ABSTRACT
Objective To investigate the effectiveness and the safety of intrahepatic arterial infusion of recombinant human endostatin combined with transcatheter arterial chemoembolization (TACE) for the treatment of advanced hepatocellular carcinoma. Methods Forty patients with advanced hepatocellular carcinoma were equally and randomly divided into study group and control group. Patients in study group received intrahepatic arterial infusion of recombinant human endostatin together with TACE, while patients in control group received conventional TACE only. Within one year after the treatment, non-scheduled CT (or MRI) and DSA were re-examined. The recurrence or metastasis of the tumor and the formation of tumor angiogenesis were surveyed and assessed. Changes in tumor size and AFP, halfand one-year survival rates, the living quality as well as the side effects were compared between two groups. Results The one-year survival rate of study group was 75% (15 / 20), which was significantly higher than that of control group (60%, 12/20), with P